Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01153672 · ClinicalTrials.gov registry record · NA

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

A NA study of Stage IV Breast Cancer and Recurrent Breast Cancer, sponsored by University of Washington.

Completed
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT01153672: Completed NA study of Stage IV Breast Cancer and Recurrent Breast Cancer, sponsored by University of Washington.

NCT01153672 is a NA study of Stage IV Breast Cancer and Recurrent Breast Cancer that has completed, run by University of Washington. The registered enrollment target is 8 participants, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01153672, a NA study of Stage IV Breast Cancer and Recurrent Breast Cancer, has completed, sponsored by University of Washington.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug

Primary Outcome

Conventional imaging (CT, bone scan) was performed at baseline and at week 8 and tumor response assessed by RECIST criteria

Conditions Studied

Stage IV Breast Cancer Recurrent Breast Cancer Male Breast Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • PROCEDURE biopsy
  • DRUG vorinostat
  • PROCEDURE positron emission tomography
  • RADIATION F-18 16 alpha-fluoroestradiol

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2010-11
Est. Completion 2016-08-11
Phase NA
University of Washington

1,048 total trials

What the finished NCT01153672 record still lists

NCT01153672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 66-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (88% lower).

The record links to 3 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.

NCT01153672 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT01153672 about?

NCT01153672 is a clinical study titled "Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy". This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tu...

What is the current status of trial NCT01153672?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2010-11. Estimated completion is 2016-08-11.

What conditions does trial NCT01153672 study?

This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Cancer, Male Breast Cancer.

What interventions are being tested in trial NCT01153672?

The interventions under investigation include: laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), vorinostat (DRUG), positron emission tomography (PROCEDURE), F-18 16 alpha-fluoroestradiol (RADIATION).

Who is sponsoring clinical trial NCT01153672?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01153672 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01153672's enrollment target sits among peer trials

8 31st of 30 the lowest of 30 other Stage IV Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IV Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01153672, the US trial registry maintained by the National Library of Medicine. NCT01153672 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.